Showing 521-530 of 9757 results for "".
Quantel Derma LEDA Diode Laser System - Hair Removal at the Speed of Light
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/quantel-derma-leda-diode-laser-system-hair-removal-at-the-speed-of-light/19447/LEDA is the expandable platform system for permanent hair removal at the speed of light. LEDA applies photodynamic therapy (PDT) for the treatment of acne, Psoriasis, Vitiligo & atopic dermatitis, and for gentle skin rejuvenation. The diode laser system LEDA EPI, for hair removal, has a large spA Closer Look at OX40 Pathway Modulation
https://practicaldermatology.com/programs/practical-dermatology-type-ii-inflammation-journal-club/a-closer-look-at-ox40-pathway-modulation/50890/Walter Liszewski, MD, talks with Matthew Zirwas, MD, about the potential therapeutic applications, based on the article “Targeting the OX40-OX40L pathway: A new era in atopic dermatitis management by T-cell rebalancing,”1 as well as the risks of therapies targeting the OX40 pathway.The Future of Customized Treatments Within the Atopic Dermatitis Pipeline
https://practicaldermatology.com/programs/dermatology-hub-neuroimmune-network/the-future-of-customized-treatments-within-the-atopic-dermatitis-pipeline/37165/Practical Dermatology Editorial Board member Peter Lio, MD, a Clinical Assistant Professor of Dermatology and Pediatrics at Northwestern University Feinberg School of Medicine, discusses the potential impact of new developments in atopic dermatitis research.Dermwire TV Extra: The Global Access to Skin Health Observatory
https://practicaldermatology.com/series/dermwire-tv/global-access-skin-health-observatory/29873/Esther Freeman, MD, PhD, Director of Global Health Dermatology at Massachusetts General Hospital and Harvard Medical School, and Vice Chair of the International Foundation of Dermatology with the International League of Dermatological Societies (ILDS), talks with Practical Dermatology about her workNoah Worcester 2024: Dr. Mesinkovska on Alopecia Areata
https://practicaldermatology.com/conferences/noah-worcester-2024/noah-worcester-2024-dr-mesinkovska-alopecia-areata/24586/Natasha Atanaskova Mesinkovska. MD, PhD, summarizes her lecture on JAK inhibitors and minoxidil at the 2024 Noah Worcester Dermatological Society meeting.Aesthetic Advances: New Technology
https://practicaldermatology.com/conferences/cosmetic-surgery-forum-2022/aesthetic-advances-new-technology/20160/Suneel Chilukuri, MD discusses the benefits of some of the new devices he’s using to improve outcomes for his aesthetic patients. He says BTL’s Emface offers him the ability to tighten and tone the facial muscles and lift neck muscles. He describes the benefits of the Sylfirm X RF microneedling systDermWire TV: Adbry Approved; Syringoma Option; Confusion over Vaccines and Injectables
https://practicaldermatology.com/series/dermwire-tv/dermwire-tv-adbry-approved-syringoma-option-confusion-over-vaccines-and-injectables/20041/Adbry (tralokinumab) from Leo Pharma is the newest biologic approved for moderate to severe atopic dermatitis in adults and is the first IL-13 blocker approved in the US. Pulse Bioscience’s nano-pulse stimulation (NPS) technology shows potential for the treatment of syringoma in a feasibility studyDermWireTV: Cosentyx for Kids; Anifrolumab for SLE, Tremfya in PsA at EULAR
https://practicaldermatology.com/topics/psoriasis/dermwiretv-cosentyx-for-kids-anifrolumab-for-sle-tremfya-in-psa-at-eular/19948/FDA has approved Cosentyx (secukinumab) from Novartis for patients as young as six years old. The 2nd Annual San Diego Dermatology Symposium kicks off as a live Virtual Experience next Friday. A post-hoc analysis of pooled data from the TULIP Phase 3 clinical trials shows that anifrolumab improvesNovel Treatments for Acne
https://practicaldermatology.com/topics/acne-rosacea/novel-treatments-for-acne/19761/Joshua Zeichner, MD discusses three new treatments now available in the acne treatment armamentarium. For patients with severe acne, a new low-dose isotretinoin in a micronized formulation allows for better absorption, even without food. Dr. Zeichner also discusses the benefits of a new topical retiAtopic Dermatitis: Rethinking the “Typical” Patient
https://practicaldermatology.com/topics/atopic-dermatitis/atopic-dermatitis-rethinking-the-typical-patient/19666/It's possible to make generalities about the experience of atopic dermatitis, but it's increasingly clear that there is no "typical" patient. Zelma Chiesa Fuxench, MD discusses the latest findings on the signs and symptoms of AD and the populations affected.